TWI887362B - 抗內皮脂肪酶抗體之配製物 - Google Patents
抗內皮脂肪酶抗體之配製物 Download PDFInfo
- Publication number
- TWI887362B TWI887362B TW110106493A TW110106493A TWI887362B TW I887362 B TWI887362 B TW I887362B TW 110106493 A TW110106493 A TW 110106493A TW 110106493 A TW110106493 A TW 110106493A TW I887362 B TWI887362 B TW I887362B
- Authority
- TW
- Taiwan
- Prior art keywords
- seq
- antibody
- formulation
- ser
- drug formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980658P | 2020-02-24 | 2020-02-24 | |
| US62/980,658 | 2020-02-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202146046A TW202146046A (zh) | 2021-12-16 |
| TWI887362B true TWI887362B (zh) | 2025-06-21 |
Family
ID=77492003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110106493A TWI887362B (zh) | 2020-02-24 | 2021-02-24 | 抗內皮脂肪酶抗體之配製物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230131324A1 (https=) |
| EP (1) | EP4110290A4 (https=) |
| JP (1) | JP2023514721A (https=) |
| CN (1) | CN115297838A (https=) |
| AU (1) | AU2021227871A1 (https=) |
| CA (1) | CA3211692A1 (https=) |
| TW (1) | TWI887362B (https=) |
| WO (1) | WO2021173537A1 (https=) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI357820B (en) * | 2003-04-04 | 2012-02-11 | Genentech Inc | High concentration antibody and protein formulatio |
| TW201613982A (en) * | 2014-09-11 | 2016-04-16 | Shionogi & Co | Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507808B2 (en) * | 2002-12-12 | 2009-03-24 | Isis Pharmaceuticals, Inc. | Modulation of endothelial lipase expression |
| AR060487A1 (es) * | 2006-04-21 | 2008-06-18 | Xoma Technology Ltd | Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40 |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| AU2010221156A1 (en) * | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
| WO2012076670A2 (en) * | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| JP6635655B2 (ja) * | 2011-12-08 | 2020-01-29 | アムジエン・インコーポレーテツド | ヒトlcat抗原結合タンパク質および治療法におけるそれらの使用 |
| CN104768578A (zh) * | 2012-10-25 | 2015-07-08 | 米迪缪尼有限公司 | 稳定的低粘度抗体配制品 |
| WO2015095568A1 (en) * | 2013-12-18 | 2015-06-25 | Kelvin Lee | Reduction of lipase activity in product formulations |
| CA2959571A1 (en) * | 2014-09-03 | 2016-03-10 | Medimmune Limited | Stable anti-il-4r-alpha antibody formulation |
| JP7377596B2 (ja) * | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
-
2021
- 2021-02-23 JP JP2022550151A patent/JP2023514721A/ja active Pending
- 2021-02-23 CA CA3211692A patent/CA3211692A1/en active Pending
- 2021-02-23 EP EP21760163.2A patent/EP4110290A4/en active Pending
- 2021-02-23 WO PCT/US2021/019213 patent/WO2021173537A1/en not_active Ceased
- 2021-02-23 CN CN202180016623.6A patent/CN115297838A/zh active Pending
- 2021-02-23 US US17/801,670 patent/US20230131324A1/en active Pending
- 2021-02-23 AU AU2021227871A patent/AU2021227871A1/en active Pending
- 2021-02-24 TW TW110106493A patent/TWI887362B/zh active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI357820B (en) * | 2003-04-04 | 2012-02-11 | Genentech Inc | High concentration antibody and protein formulatio |
| TW201613982A (en) * | 2014-09-11 | 2016-04-16 | Shionogi & Co | Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3211692A1 (en) | 2023-09-02 |
| JP2023514721A (ja) | 2023-04-07 |
| CN115297838A (zh) | 2022-11-04 |
| EP4110290A1 (en) | 2023-01-04 |
| EP4110290A4 (en) | 2024-06-05 |
| US20230131324A1 (en) | 2023-04-27 |
| TW202146046A (zh) | 2021-12-16 |
| WO2021173537A1 (en) | 2021-09-02 |
| AU2021227871A1 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102589598B1 (ko) | 단클론 항체의 제형 | |
| JP6416841B2 (ja) | 医薬製剤 | |
| CN102770157B (zh) | 抗体的配制品 | |
| JP2020079242A (ja) | 高濃度の抗vegf抗体を含有する安定状態のタンパク質溶液製剤 | |
| CN106061468B (zh) | 包含TNFR和Fc区的融合蛋白的液体制剂 | |
| JP7089121B2 (ja) | 高濃度の抗vegf抗体を含有するタンパク質溶液製剤 | |
| JP7398958B2 (ja) | 安定的抗osmr抗体製剤 | |
| TW202034901A (zh) | 抗體配方 | |
| AU2021250949A1 (en) | Liquid Pharmaceutical Composition | |
| JP2022519796A (ja) | 抗pcsk9抗体を含む安定製剤 | |
| TWI887362B (zh) | 抗內皮脂肪酶抗體之配製物 | |
| CN116172947A (zh) | 一种含特异性结合vegf和ang2的双特异性抗体的药物组合物 | |
| HK40083646A (en) | Formulations of anti-endothelial lipase antibodies | |
| KR20230121797A (ko) | 항-il5r 항체 제형 | |
| HK40103088A (zh) | 抗il5r抗体配制品 | |
| AU2022372646A1 (en) | Formulations | |
| TW202541845A (zh) | 穩定醫藥製劑 |